Search

Your search keyword '"Genth-Zotz, S."' showing total 123 results

Search Constraints

Start Over You searched for: Author "Genth-Zotz, S." Remove constraint Author: "Genth-Zotz, S."
123 results on '"Genth-Zotz, S."'

Search Results

1. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

2. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

6. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

9. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

10. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial

14. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

17. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients

18. Koronare Restenose

20. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

21. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

22. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy

23. Ezetimibe added to statin therapy after acute coronary syndromes

24. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

25. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

26. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

27. Extended thromboprophylaxis with betrixaban in acutely ill medical patients

28. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

29. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

30. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

31. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

34. High- versus low-dose ACE inhibition in chronic heart failure. A double-blind, placebo-controlled study of imidapril

36. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study

38. MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing.

41. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

44. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

46. Survival and quality of life after early discharge in low-risk pulmonary embolism.

47. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.

48. [Coronary restenosis].

49. Gender-specific diagnostic performance of a new high-sensitivity cardiac troponin I assay for detection of acute myocardial infarction.

50. Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure.

Catalog

Books, media, physical & digital resources